medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2010, Number 11

<< Back Next >>

Ginecol Obstet Mex 2010; 78 (11)

Atención de la resistencia a la insulina en el síndrome de ovarios poliquísticos

Hernández-Valencia M, Hernández-Rosas M, Zárate A

Language: Spanish
References: 30
Page: 612-616
PDF size: 301.10 Kb.


ABSTRACT

Polycystic ovary syndrome (PCOS) constitutes the main cause of anovulatory sterility with a near occurrence to 7 %. The PCOS have not a constant hormonal profile, for it has been necessary the employment of approaches like those of Rotterdam to establish the presence of this dysfunction. A surprising discovery was the demonstration of the effect of the insulin on the ovary, that which modified the concept of the specificity in the action of the insulin on certain tissues, therefore a resistance stage to the action of insulin induces a compensatory hyperinsulinism to try to stimulate all the tissues, but in secondary form increases the dysfunction of the ovarian steroidogenesis. There are drugs known as “insulin sensitizers”, used in the treatment of certain forms of diabetes mellitus, among those are metformin and tiazolidinediones (roziglitazone and pioglitazone), recently a compound has been used with formulation of amino acids and oligoelements (Diamel) that neutralizes the free radicals reestablishing the intracellular signs of the insulin at cellular level. It is important to guide that long term without correct the PCOS could have back effect since the insulin resistance is associates to a higher risk of increasing impaired glucose, diabetes, dyslipidemia, atherosclerosis and vascular disease. Therefore, preventive measures should be implemented that at present time are to the reach.


REFERENCES

  1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.

  2. Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol Obstet Invest 2010;69:274-280.

  3. Pembe AB, Abeid MS. Polycystic ovaries and associated clinical and biochemical features among women with infertility in a tertiary hospital in Tanzania. Tanzan J Health Res 2009;11:175-180.

  4. Zárate A, Hernández-Valencia M. Síndrome de ovarios poliquísticos: una entidad sistémica metabólica. Rev Med UNAM 1997;40:230-233.

  5. Fauser BCJM. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). The Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop group. Hum Reprod 2004;19:41-47.

  6. Franks S. Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006;91:786-789.

  7. Azziz R. Diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006;91:781-785.

  8. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis EA, et al. The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-488.

  9. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev 1997;18:774-800.

  10. Morán C. Conceptos actuales en hiperandrogenismo, síndrome de ovario poliquístico y resistencia a la insulina. Rev Endo Nut 2006;14:25-32.

  11. Aquino P, Hernández-Valencia M, Hicks J, Fonseca M. Participación del factor de crecimiento insulinoide (IGF) en el síndrome de ovario poliquístico (síndrome de ovarios poliquísticos). Ginecol Obstet Mex 1999;66:267-271.

  12. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c 17 activity and serum free testosterone after reduction in insulin secretion in women with polycystic ovary syndrome. N Engl J Med 1996;335:617-623.

  13. Zárate A, Morán C, Hernández-Valencia M, Ochoa R. Síndrome de Stein-Levental: un trastorno sistémico metabólicohormonal. Rev Med Inst Mex Seguro Soc 2003;41:165-174.

  14. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clinical Endocrinology 2005;62:1-6.

  15. Hernández-Valencia M. Repercusión en las alteraciones en los mecanismos de señalización del receptor de insulina. Rev Med Inst Mex Seguro Soc 2006;44:383-388.

  16. Katz A, Nambi SS, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410.

  17. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992;167:1807-1812.

  18. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141-154.

  19. Ketel IJG, Stehouwer CDA, Serné EH, Korsen TJM, Hompes PGA, Smulders YM, de Jongh RT, Homburg R, Lambalk CB. Obese but not normal-weight women with polycystic ovary síndrome are characterized by metabolic and microvascular insulin resistance. J Clin Endocrinol Metabol 2008;10;1210-1214.

  20. Bachmann GA. Polycystic ovary syndrome: metabolic challenges and new treatment options. Am J Obstet Gynecol 1998;179:87-88.

  21. Moghetti P, Tosi F, Tosti A, Negri C, et al. Comparison of spirolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:89-94.

  22. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, by hyperandrogenemia, and systolic blood pressure faciliting normal menses and pregnancy. Metabolism 1994;43:647-654.

  23. Cosma M, Swiglo BA, Flynn DN, Kurtz DM, et al. Insulin sensitizers for the treatment of hirsutism : a systematic review and mataanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008;93:1135-1142.

  24. Zárate A, Hernández-Valencia M, Fonseca M, Ochoa R. Empleo de metformina en el manejo de adolescentes con el síndrome de ovarios poliquísticos. Ginecol Obstet Mex 1997;65:504-508.

  25. Hunter MH, Sterret JJ. Polycystic ovary syndrome: it’s not just infertility. Am Family Phys 2000;12:456-459.

  26. Legro RS. Impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women: do we need a new drug? J Clin Endocrinol Metab 2008;93:4218-4220.

  27. Hernandez YJA, Vargas GD. Utility of Diamel in patients with type 2 diabetes mellitus receiving combination therapy with glibenclamide. Av Diabetol 2006;23:284-290.

  28. Tissue ascorbic acid and polyol pathway metabolism in experimental diabetes. Lindsay RM. Diabetologia 1998;41:516-523.

  29. Pierport T, Mckeique PM, Isaacs AJ, Jacobs HS. Mortality of women with polycystic ovary syndrome at long term follow-up. J Clin Epidemiol 1998 ;;51:581-586.

  30. Hamburg R. Polycystic ovary syndrome -from gynecological curiosity to multisystem endocrinopathology. Hum Reprod 1996;10:29-39.




2020     |     www.medigraphic.com